Projected outcomes of reduced-biopsy management of Grade Group 1 prostate cancer: implications for relabeling
Prostate-specific antigen-based active monitoring could substantially reduce biopsy frequency; however, a precision strategy based on an individual upgrading risk is most likely to minimize delays in detection of disease progression. This strategy may be preferred if active surveillance is deintensified under relabeling, provided patient adherence remains unaffected.
Authors
- Yingye Zheng (ORCID: https://orcid.org/0000-0002-3078-4200)
- Ingrid J. Hall (ORCID: https://orcid.org/0000-0001-5864-6195)
- Eveline A.M. Heijnsdijk (ORCID: https://orcid.org/0000-0002-4890-6069)
- Roman Gulati (ORCID: https://orcid.org/0000-0002-7592-6567)
- Yibai Zhao
- Scott E. Eggener (ORCID: https://orcid.org/0000-0001-6677-2503)
- Michael C. Haffner (ORCID: https://orcid.org/0000-0003-0809-6425)
- Ruth Etzioni (ORCID: https://orcid.org/0000-0002-9164-6370)
- Adam S. Kibel
- Dimitris Rizopoulos (ORCID: https://orcid.org/0000-0001-9397-0900)
- Angelo M. De Marzo (ORCID: https://orcid.org/0000-0003-4847-5307)
- Matthew R. Cooperberg (ORCID: https://orcid.org/0000-0003-4339-6685)
- Menghan Liu (ORCID: https://orcid.org/0000-0002-4371-9782)
- Lisa F. Newcomb (ORCID: https://orcid.org/0000-0003-3505-3754)
- Z. Yang (ORCID: https://orcid.org/0000-0003-2937-9782)
- Kehao Zhu (ORCID: https://orcid.org/0009-0002-6548-4707)
Institutions
- Brigham and Women's Hospital (US)
- Centers for Disease Control and Prevention (US)
- Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa (ZA)
- Johns Hopkins University (US)
- University of California, San Francisco (US)
- University of Washington (US)
- Johns Hopkins Medicine (US)
- Erasmus MC (NL)
- University of Chicago Medical Center (US)
- Fred Hutch Cancer Center (US)
- National Center for Chronic Disease Prevention and Health Promotion (US)
- Erasmus University Rotterdam (NL)
Publication Details
- Journal
- JNCI Journal of the National Cancer Institute
- Published
- 2024-11-20
- DOI
- https://doi.org/10.1093/jnci/djae296
- Citations
- 1
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.42
Funders
- Centers for Disease Control and Prevention
- National Cancer Institute